Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific MeetingGlobeNewsWire • 11/09/22
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual MeetingGlobeNewsWire • 09/06/22
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22
Optinose Reports Second Quarter 2022 Financial Results and Operational UpdatesGlobeNewsWire • 08/11/22
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen ProgramGlobeNewsWire • 07/13/22
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen ProgramGlobeNewsWire • 07/08/22
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic SinusitisGlobeNewsWire • 06/13/22
OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Optinose Reports First Quarter 2022 Financial Results and Operational UpdatesGlobeNewsWire • 05/12/22
OptiNose, Inc. (OPTN) CEO Peter Miller on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/08/22
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational HighlightsGlobeNewsWire • 03/08/22
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic SinusitisGlobeNewsWire • 03/07/22